{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:17Z","timestamp":1789587017383,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejphar.2023.176215","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T03:53:26Z","timestamp":1701748406000},"page":"176215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes"],"prefix":"10.1016","volume":"962","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-3294","authenticated-orcid":false,"given":"Simone Anna","family":"Melander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashref","family":"Kayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Vietz","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.176215_bib1","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/bcp.13688","article-title":"MEDI0382, a GLP-1\/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study","volume":"84","author":"Ambery","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176215_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176215_bib3","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1111\/bph.14383","article-title":"A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway","volume":"175","author":"Bao","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176215_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176215_bib5","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176215_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejphar.2023.176215_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14656566.2023.2208746","article-title":"Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes","volume":"24","author":"Brodosi","year":"2023","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2023.176215_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MEG.0b013e32832fcdf0","article-title":"Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain","volume":"22","author":"Caballer\u00eda","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176215_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176215_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/bip.22072","article-title":"Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents","volume":"98","author":"Day","year":"2012","journal-title":"Biopolymers"},{"key":"10.1016\/j.ejphar.2023.176215_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2023.176215_bib15","first-page":"12423","article-title":"Novel peptidic dual GLP-1\/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound","author":"Ding","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2023.176215_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis inob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176215_bib17","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2023.176215_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2023.176215_bib20","first-page":"1","article-title":"Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: a comparative study between mice and non-human primates","author":"Elvert","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2023.176215_bib22","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.176215_bib23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2023.176215_bib24","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.176215_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101801","article-title":"Results from three phase 1 trials of NNC9204-1177, a glucagon\/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity","volume":"78","author":"Friedrichsen","year":"2023","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.176215_bib28","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.orcp.2015.01.003","article-title":"Elevation of branched-chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment","volume":"9","author":"Iwasa","year":"2015","journal-title":"Obes. Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2023.176215_bib30","doi-asserted-by":"crossref","unstructured":"Jastreboff, A.M., Kaplan, L.M., Fr\u00edas, J.P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M.L., Retatrutide Phase 2 Obesity Trial Investigators, 2023. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N. Engl. J. Med. 1\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2301972...","DOI":"10.1056\/NEJMoa2301972"},{"key":"10.1016\/j.ejphar.2023.176215_bib31","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.1152\/ajpendo.00023.2018","article-title":"Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis","volume":"315","author":"Kalavalapalli","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.176215_bib32","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Kapitza","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2023.176215_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1124\/jpet.122.001440","article-title":"The effects of dual GLP-1\/glucagon receptor agonists with different receptor selectivity in mouse models of obesity and nonalcoholic steatohepatitis","volume":"384","author":"Kayed","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.176215_bib34","doi-asserted-by":"crossref","DOI":"10.2337\/db19-991-P","article-title":"991-P: potential of a novel long-acting glucagon analog, HM15136, for the treatment of obesity","volume":"68","author":"Kim","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.176215_bib35","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.176215_bib36","doi-asserted-by":"crossref","DOI":"10.2337\/db22-334-OR","article-title":"334-OR: pemvidutide (ALT-801) , a balanced (1:1) GLP-1\/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight\/obesity","volume":"71","author":"Klein","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.176215_bib37","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176215_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib39","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ejphar.2023.176215_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00726-014-1894-9","article-title":"Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease","volume":"47","author":"Lake","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejphar.2023.176215_bib41","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176215_bib42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1872-034X.2011.00946.x","article-title":"Enzyme-linked immunosorbent serum assay specific for the 7S domain of collagen type IV (P4NP 7S): a marker related to the extracellular matrix remodeling during liver fibrogenesis","volume":"42","author":"Leeming","year":"2012","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2023.176215_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2023.176215_bib44","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176215_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112496","article-title":"A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice","volume":"203","author":"Ma","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176215_bib46","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176215_bib47","first-page":"1","article-title":"Revisiting the complexity of GLP-1 action-from sites of synthesis to receptor activation","volume":"0","author":"McLean","year":"2020","journal-title":"Endocr. Rev."},{"issue":"44","key":"10.1016\/j.ejphar.2023.176215_bib48","first-page":"1433","article-title":"Erratum to: effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"2021","author":"Nahra","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2023.176215_bib49","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2337\/db18-1806-P","article-title":"Glucagon regulates energy balance via FGF-21 signaling in the brain","volume":"67","author":"Nason","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.176215_bib50","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/S0168-8278(20)31395-7","article-title":"GLP-1\/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model","volume":"73","author":"Nestor","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176215_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.176215_bib52","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2023.176215_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cmet.2009.02.002","article-title":"A BCAA Related Metabolic Signature that differentiates obese and lean","volume":"9","author":"Newgard","year":"2009","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib54","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176215_bib55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176215_bib56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.176215_bib57","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib58","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1210\/clinem\/dgz047","article-title":"Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist","volume":"105","author":"Parker","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.176215_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0179856","article-title":"Glucose dysregulation and response to common anti-diabetic agents in the FATZO\/Pco mouse","volume":"12","author":"Peterson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176215_bib60","first-page":"575","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176215_bib61","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.176215_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2019.00930","article-title":"Novel GLP-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice","volume":"10","author":"Ren","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2023.176215_bib63","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176215_bib66","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1152\/ajpendo.00161.2015","article-title":"Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease","volume":"309","author":"Sunny","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.176215_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2023.176215_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2023.176215_bib70","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.28962","article-title":"A novel glucagon\u2010like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice","volume":"65","author":"Valdecantos","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.176215_bib71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2023.176215_bib72","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/dom.13939","article-title":"Dual glucagon-like peptide-1 receptor\/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes","volume":"22","author":"Visentin","year":"2020","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2023.176215_bib73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.176215_bib74","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.176215_bib75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2337\/dc17-1590","article-title":"Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission","volume":"41","author":"Wild","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2023.176215_bib76","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.ijo.0803344","article-title":"Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial","volume":"30","author":"Wynne","year":"2006","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2023.176215_bib77","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1478-3231.2006.01311.x","article-title":"Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures","volume":"26","author":"Zelber-Sagi","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2023.176215_bib78","article-title":"BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"101633","author":"Zimmermann","year":"2022","journal-title":"Mol. Metabol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992300729X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992300729X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:23:55Z","timestamp":1762143835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992300729X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":71,"alternative-id":["S001429992300729X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176215","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"176215"}}